LEO Pharma files IND application to FDA for a clinical study of JW1601/LP0190 in the US
- Based on the successfully completed single-dose part of the phase I clinical trial in Korean population carried out by JW Pharmaceutical, LEO Pharma files IND application to the FDA for study of JW1601/LP0190 in US set to start in 2020.
Ballerup, Denmark, and Seoul, Korea, August 27th, 2019: LEO Pharma, a global leader in medical dermatology, and Korean JW Pharmaceutical today announced that LEO Pharma has filed an Investigational New Drug Application (IND) to the US Food and Drug Administration (FDA) for a pharmacokinetics study in the US.
The filing is based on the two companies’ ongoing collaboration on the development of JW1601/LP0190, an oral treatment for atopic dermatitis for which JW Pharmaceutical out-licensed their investigatory drug to LEO Pharma in August 2018. JW Pharmaceutical has since January this year conducted phase 1 clinical trial consisting of a single dose and repeated dose studies in healthy adults. Recently the single dose phase for Koreans was successfully completed with acceptable safety and tolerability observed up to the highest dose, 5th cohort. Based on this trial LEO Pharma has now filed a protocol for a pharmacokinetics study in US – a small clinical trial with healthy volunteers to further evaluate the pharmacokinetics of JW016/LP0190.
“We are excited to see the progress of our collaboration with JW Pharmaceuticals that is now enabling us to file the IND application to the FDA and take the next step towards making an oral treatment for atopic dermatitis available. The unmet needs in this disease area are huge and an oral treatment will add substantially to the treatment options to the benefit of the many people living with this disease”, says Kim Kjoeller, Executive Vice President, Global Research & Development at LEO Pharma.
S.Y Lee, Senior Executive Vice President, Chief of Corporate Development Division said, “As the single-dose study for Koreans has been completed smoothly, LEO Pharma was able to apply for this study plan in US.” He also added that “JW Pharmaceutical will further strengthen our partnership with LEO Pharma in the future and develop JW1601 as a new drug for treatment of atopic dermatitis that will play a pivotal role in the global market.”
JW1601 is a H4R antagonist expected to have anti-pruritic and anti-inflammatory effect in atopic dermatitis. The new drug candidate is developed as an oral treatment, a more convenient route of administration with the potential to improve the compliance for the patient.
+45 3140 6180
LEO Pharma US
+1 973 637 8019
+1 862 337 0675
About LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,500 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million.
About JW PHARMACEUTICAL CORPORATION
JW Pharmaceutical Corporation has been leading Korean medicine and medical supplies market over its 70 years of history. The company focuses on the field of research and development of anti-cancer drug and etc.; manufacture and sales of hospital fluid, antibiotic and other ethical pharmaceuticals.
JW Pharmaceutical Corporation was founded in 1945 and is listed on the Korea Exchange Market under the symbol "001060 ".
More information is available at http://www.jw-pharma.co.kr/pharma/en/main.jsp.
JW1601 is an orally available histamine H4 receptor inverse agonist with anti-pruritic and anti-inflammatory dual effect. It shows anti-chemotactic activity in eosinophil shape change and therapeutic effect in spontaneous NC/Nga AD model. JW1601 is currently conducting pre-clinical toxicity study and looking for phase 1 IND submission in 2018 in Korea. JW1601 is an investigational compound that is not approved for any use in any country.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma and X-Chem Enter Into Discovery Research Agreement6.7.2021 08:00:00 CEST | Press release
Multi-target Collaboration to Focus on Identification of Novel Small Molecules for Anti- inflammatory Applications
Jesper Brandgaard ny formand for LEO Pharmas bestyrelse1.7.2021 13:00:00 CEST | Pressemeddelelse
Jesper Brandgaard bliver ny formand for LEO Pharmas bestyrelse. Han afløser Olivier Bohuon.
LEO Pharma announces European Commission approval of Adtralza® (tralokinumab) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis22.6.2021 08:00:00 CEST | Press release
NOT FOR DISTRIBUTION IN THE UK OR IRELAND BALLERUP, Denmark, JUNE 22, 2021 – LEO Pharma A/S, a global leader in medical dermatology, today announced that the European Commission (EC) has approved Adtralza® (tralokinumab) for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. The European approval makes Adtralza the first high affinity, fully human monoclonal antibody approved to specifically bind to and inhibit the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms.1,4,5
LEO Pharma initiates the first Phase 3 clinical trial with delgocitinib cream in adult patients with moderate-to-severe chronic hand eczema (CHE)18.5.2021 08:00:00 CEST | Press release
NOT FOR DISTRIBUTION IN THE UK OR IRELAND BALLERUP, Denmark, 18 May 2021 -- LEO Pharma A/S, a global leader in medical dermatology, today announced it has enrolled the first adult patient in the first of two pivotal Phase 3 clinical trials with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor, for the potential treatment of adult patients with moderate-to-severe chronic hand eczema (CHE).
LEO Pharma receives positive CHMP opinion of Adtralza® (tralokinumab) for the treatment of adults with moderate-to-severe atopic dermatitis23.4.2021 12:32:53 CEST | Press release
• If authorized, Adtralza® (tralokinumab) will be the first approved biologic that specifically targets the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms1,2 • The CHMP opinion is primarily supported by data from ECZTRA 1, 2, and 3 trials included in the Marketing Authorization Application
LEO Fondet og Nordic Capital indgår nyt partnerskab, der skal styrke LEO Pharma23.3.2021 13:00:00 CET | Pressemeddelelse
Nordic Capital, en førende global investor inden for sundhedsområdet, bliver partner med LEO Fondet og træder ind i LEO Pharma som aktiv minoritetsejer, der skal understøtte LEO Pharmas rejse mod globalt lederskab inden for medicinsk dermatologi og bidrage til at accelerere innovation og vækst. LEO Fondet er fortsat virksomhedens majoritetsejer.
LEO Pharma delivered on strategic ambitions and showed resilience during COVID-19 pandemic in 202023.3.2021 13:00:00 CET | Press release
Ballerup, Denmark, March 23, 2021. LEO Pharma net sales recovered from COVID-19 impact during the year, reaching DKK 10.1 billion (-6%) Strategic psoriasis products Enstilar® and Kyntheum® continued to grow and gain market share. Total revenue declined 1.8% when excluding discontinued or divested products. This was offset by the impact of coronavirus lockdowns, generics in Europe and further price pressure in the US. - Revenue of Enstilar® increased 3% (+10% in Europe) to DKK 1,125 million, compared to topical market declining 2% - Revenue of Kyntheum® increased 40% to DKK 467 million compared to market growth of biologics for psoriasis of 16% Strategic projects progressed as planned while LEO Pharma ensured business continuity In response to the coronavirus pandemic, LEO Pharma successfully implemented a plan to ensure safety and corporate responsibility, continuity of supply, and continuity of strategic projects. - Supply chain and clinical trials continued uninterrupted - Introduced
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom